Security
OKYO PHARMA LTD ORD NPV (Guernsey) · EMMLF
EMMLFOTCCommon stockHistorical · closed May 22, 2023CIK 1849296Updated Oct 7, 2026
Current security for this SEC filerOKYO · NASDAQ
EMMLF price & chart
Historical security
This listing closed May 22, 2023. Live provider charts are shown only for current listings.
Current security: OKYO
About the company
OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossUSD | -4,706,292Source | -16,825,461Source | -13,271,685Source | -5,431,045Source |
| Additional Financial Items | ||||
| AdjustmentsForCurrentTaxOfPriorPeriodUSD | -3,263,830Source | -32,864Source | -12,202Source | -277,239Source |
| AdjustmentsForIncomeTaxExpenseUSD | -3,263,779Source | 22,416Source | — | — |
| AdjustmentsForSharebasedPaymentsUSD | 734,989Source | 1,121,273Source | 1,286,128Source | 1,737,876Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsUSD | -96,978Source | 55,183Source | 51,192Source | -9,230Source |
| ProceedsFromIssuingSharesUSD | — | — | 7,323,354Source | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Additional Financial Items | ||||
| ApplicableTaxRatenumber | 0.19Source | 0.19Source | 0.19Source | 0.19Source |
| BasicEarningsLossPerShareUSD per share | -0.2Source | -0.57Source | -0.61Source | — |
| CurrentTaxExpenseIncomeUSD | 51Source | 55,280Source | — | -509,282Source |
| DepreciationAndAmortisationExpenseUSD | 2,563Source | 3,866Source | 3,797Source | 2,423Source |
| DilutedEarningsLossPerShareUSD per share | -0.2Source | -0.57Source | -0.61Source | — |
| EmployeeBenefitsExpenseUSD | 2,112,210Source | 2,662,909Source | 1,918,330Source | 1,129,279Source |
| FinanceCostsUSD | 878,174Source | 1,053,313Source | 96,687Source | — |
| FinanceIncomeUSD | 5,473Source | — | — | — |
| IncomeTaxExpenseContinuingOperationsUSD | 3,263,779Source | -22,416Source | 12,202Source | 786,521Source |
| PostemploymentBenefitExpenseDefinedContributionPlansUSD | 6,277Source | 5,598Source | 6,510Source | 2,622Source |
| ProfessionalFeesExpenseUSD | 1,005,883Source | 1,377,774Source | 1,432,926Source | 1,143,300Source |
| ProfitLossBeforeTaxUSD | -7,970,071Source | -16,803,045Source | -13,283,887Source | -6,217,566Source |
| ResearchAndDevelopmentExpenseUSD | 2,254,244Source | 8,243,571Source | 6,337,698Source | 1,301,178Source |
| RevenueFromInterestUSD | 5,473Source | — | — | — |
Offerings
Registration 333-293145
Filing attachments
ex99-1.htm · 6-K · 2026-10-06
Exhibit 99.1 OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain NEPTUNE is evaluating urcosimod as a potential first-in-class treatment for neuropathic corneal pain First patients enrolled by Dr. Melissa Toyos at Toyos Clinic in Nashville, TN London and New York, NY, October 6, 2026. OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neur…
Read attachment ↗ex99-1.htm · 6-K · 2026-09-29
Exhibit 99.1 OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences OKYO demonstrates continued commitment to optometry and ophthalmology London and New York, NY, September 29, 2026. OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that it will present and participate at upcoming ophthalmic c…
Read attachment ↗ex99-1.htm · 6-K · 2026-09-09
Exhibit 99.1 OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026 Company to engage with the global ophthalmology and investment community as it advances urcosimod through its global Phase 3 pivotal trial for neuropathic corneal pain London and New York, NY, September 9, 2026. OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and ante…
Read attachment ↗ex99-1.htm · 6-K · 2026-09-08
Exhibit 99.1 OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference London and New York, NY, September 8, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced participation at the Cantor Global Healthcare Conference being held September 9-11, 2026. Details of the event are as follows: Pres…
Read attachment ↗ex99-1.htm · 6-K · 2026-07-28
Exhibit 99.1 OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer London and New York, NY, July 28, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that Raj Patil, PhD, Chief Scientific Officer of OKYO Pharma has increased his holdings with the purchase of 3,363 of the Company’s ordinary shares on NASDAQ…
Read attachment ↗ex99-1.htm · 6-K · 2026-07-27
Exhibit 99.1 OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026 London and New York, NY, July 27, 2026. OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced its participation in the BTIG Biotechnology Conference 2026 taking place virtually on July 28-29, 2026. Company Participation : Robert J. Dempsey, Chief Ex…
Read attachment ↗